Imaging surveillance for children with predisposition to renal tumors

Srinivasan, Abhay; Saade-Lemus, Sandra; Servaes, Sabah; Acord, Michael; Reid, Janet R.; Anupindi, Sudha A.; States, Lisa J.

doi:10.1007/s00247-019-04432-2

Cited by 12 publications

(12 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surveillance recommendations are available and include chest, thyroid and abdominal imaging, in CUAJ -Residents' Room Caron et al Case: Pediatric cystic nephroma associated with DICER1 mutation 3 © 2020 Canadian Urological Association addition to individual, family and provider education. [9,10] The actual surveillance recommendations for kidney imaging of a patient with DICER1 mutation is an U/S every six months for the first eight years of life, and every year until 12 years old [8,10,11] although the clinical utility and cost-effectiveness of this surveillance strategy has not been formally studied yet. To date, the literature is scarce concerning the follow-up recommendations after resection of CN or for stable CN.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Case – Bilateral and recurrent pediatric cystic nephroma associated with DICER1 mutation

Caron

Turcotte²,

Pelland‐Marcotte³

et al. 2020

CUAJ

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…However, at least an abdominal U/S every six months should be obtained for the first few years after a CN diagnosis. [8,10,11] Our practice has been to perform U/S every three months for children with a history of CN.…”

Section: Discussionmentioning

confidence: 99%

Case – Bilateral and recurrent pediatric cystic nephroma associated with DICER1 mutation

Caron

Turcotte²,

Pelland‐Marcotte³

et al. 2020

CUAJ

View full text Add to dashboard Cite

show abstract

“…28,[47][48][49] Children with genetic predisposition syndromes should receive routine screening for possible development of WT. 16,[50][51][52][53] The goal is to identify and treat the WT at an early stage when the tumor is small and asymptomatic; this may hopefully be accomplished by partial nephrectomy, preserving renal tissue. It is important to note that the presence of a genetic predisposition syndrome does not mean that a child will develop WT.…”

Section: Genetic Predisposition Conditionsmentioning

confidence: 99%

Wilms Tumor (Nephroblastoma), Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Balis

Green

Anderson

et al. 2021

Journal of the National Comprehensive Cancer Network

View full text Add to dashboard Cite

The NCCN Guidelines for Wilms Tumor focus on the screening, diagnosis, staging, treatment, and management of Wilms tumor (WT, also known as nephroblastoma). WT is the most common primary renal tumor in children. Five-year survival is more than 90% for children with all stages of favorable histology WT who receive appropriate treatment. All patients with WT should be managed by a multidisciplinary team with experience in managing renal tumors; consulting a pediatric oncologist is strongly encouraged. Treatment of WT includes surgery, neoadjuvant or adjuvant chemotherapy, and radiation therapy (RT) if needed. Careful use of available therapies is necessary to maximize cure and minimize long-term toxicities. This article discusses the NCCN Guidelines recommendations for favorable histology WT.

show abstract

“…In a series including 15 patients who underwent quarterly ultrasound and 59 who did not, no screened patients were diagnosed with stage III or higher WT, while 42% of the tumors diagnosed with non-screened children were stage III or higher (P<0.003) (38). Ultrasound is an optimal screening tool, as it is widely available, lacks ionizing radiation, and can be performed without sedation (24). Magnetic resonance imaging (MRI) has been suggested as a screening modality for certain cancer predisposition syndromes.…”

Section: Screening/surveillancementioning

confidence: 99%

Syndromic Wilms tumor: a review of predisposing conditions, surveillance and treatment

Liu¹,

Suson²

2020

Transl Androl Urol

View full text Add to dashboard Cite

Predisposing syndromes associated with an increased risk of Wilms tumor (WT) are responsible for 9-17% of all cases of the malignancy. Due to an earlier age at WT diagnosis and an increased incidence of bilateral and metachronous disease, management of syndromic WT warrants a distinct approach from that of non-syndromic WT. This review of English-language manuscripts about WT focuses on the most common syndromes, surveillance protocols and current treatment strategies. Highlighted syndromes include those associated with WT1, such as WAGR (Wilms-Aniridia-Genitourinary-mental Retardation), Denys-Drash syndrome (DDS), and Frasier syndrome, 11p15 defects, such as Beckwith-Wiedemann syndrome (BWS), among others. General surveillance guidelines include screening renal or abdominal ultrasound every 3-4 months until the age of 5 or 7, depending on the syndrome. Further, some of the predisposing conditions also increase the risk of other malignancies, such as gonadoblastoma and hepatoblastoma. With promising results for nephron-sparing surgery in bilateral non-syndromic WT, there are increasing reports and recommendations to pursue nephron-sparing for these patients who are at greater risk of bilateral, metachronous lesions. In addition to the loss of renal parenchyma from malignancy, many patients are at risk of developing renal insufficiency as part of their syndrome. Although there may be some increase in the complication rate, recurrence free survival seems equivalent. Some conditions require specialized approaches to adjuvant therapy, as their syndrome may make them especially susceptible to side effects.

show abstract

Imaging surveillance for children with predisposition to renal tumors

Cited by 12 publications

References 38 publications

Case – Bilateral and recurrent pediatric cystic nephroma associated with DICER1 mutation

Case – Bilateral and recurrent pediatric cystic nephroma associated with DICER1 mutation

Wilms Tumor (Nephroblastoma), Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Syndromic Wilms tumor: a review of predisposing conditions, surveillance and treatment

Contact Info

Product

Resources

About